Loading company
Annovis Bio, Inc.
ANVS · NYSE · ·
Next earnings: November 11, 2026
$1.31-5.1%Sep 29 close
- 1M
- -23.8%
- 6M
- -34.8%
- 1Y
- -36.7%
- 5Y
- -96.4%
ANVS · NYSE · ·
Next earnings: November 11, 2026
$1.31-5.1%Sep 29 close
Annovis Bio, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$14.8M | -$6.2M | -138.27% |
| Profit per share | -$0.40 | -$0.32 | -25.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Annovis Bio, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Annovis Bio, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.